Combined with reports in the literature, studies have shown that the mechanism of endometrial cancer resistance to progesterone may be related to an imbalance in the expression of progesterone receptor subtypes and to the abnormal expression or sustained activation of epidermal growth factor receptor (EGFR) and the activation its downstream signaling pathways. The gene discussed is PGR; the disease is endometrial cancer.